Would You Rather?: Goldman Sachs or The Mag7… And Structure Therapeutics CEO 1/15/26
Goldman Sachs surging to fresh records as earnings top estimates, while some Mag7 stocks continue to struggle against the broader market. So will the big bank keep bumping, or can the big tech trouble make a turnaround? Plus the weight loss drug wars are heating up, with focus turning to the GLP-1 pill. The latest…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from CNBC's "Fast Money"
See all episodes →Meta’s Rally Keeps Rocking… And A Major AI Safety Warning 9/24/26
U.S. 10-Year Yield Hits 19-Year High… And The Ripple Effects From Meta’s Muse 9/23/26
Meta’s Muse Ripple Effects… And A Coiled Spring In Google 9/22/26
Similar episodes from other shows
More like CNBC's "Fast Money" →
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.